
## Investigating Hapten Clustering as a Strategy to Enhance Vaccines against Drugs of Abuse

Karen C. Collins, Kim D. Janda\*

Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

\*Email: kdjanda@scripps.edu, phone (858) 784-2515, fax: (858) 784-2595

## ELISA data




**Figure S1**. Midpoint antibody titers from AM1-OVA and triAM1-OVA vaccinated mice (n = 5-6) as determined by ELISA using AM1-BSA or triAM1-BSA as the coating antigen. Data were obtained in duplicate. Numbers in parentheses represent the hapten density; error bars represent SEM; individual points represent individual mouse titers.

**Tables S1–S2**. Midpoint Antibody Titers from AM1-OVA and triAM1-OVA Vaccinated Mice (n = 5-6) as Determined by ELISA Using AM1-BSA and triAM1-BSA Coated Plates<sup>*a*</sup>

Vaccine	Copies per OVA molecule	Titers (AM1-BSA coating antigen)		
		21 d	42 d	56 d
AM1-OVA	11.4	$\textbf{10842} \pm 7015$	$19376 \pm 4167$	$\textbf{33518} \pm \textbf{5885}$
triAM1-OVA	2.75 (≡8.24)	$\textbf{6297} \pm \textbf{2412}$	$6056 \pm 2188$	$\textbf{7775} \pm \textbf{2857}$
Vaccine	Copies per OVA molecule	Titers (triAM1-BSA coating antigen)		
		21 d	42 d	56 d
AM1-OVA	11.4	$18247 \pm 10885$	$29405 \pm 7816$	$\textbf{45127} \pm \textbf{9572}$
triAM1-OVA	2.75 (≡8.24)	$\textbf{17390} \pm \textbf{8153}$	$16915\pm7149$	$\textbf{31874} \pm \textbf{13531}$

<sup>a</sup>Data were obtained in duplicate. Errors represent SEM.




**Figure S2**. Midpoint antibody titers from AM1-OVA, triAM1(Gly)<sub>2</sub>-OVA and AM1(Gly)<sub>2</sub>-OVA vaccinated mice (n = 5-6) as determined by ELISA using AM1-BSA, triAM1(Gly)<sub>2</sub>-BSA or AM1(Gly)<sub>2</sub>-BSA as the coating antigen. Data were obtained in duplicate. Numbers in parentheses represent the hapten density; error bars represent SEM; individual points represent individual mouse titers.

Tables S3–S5. Midpoint Antibody Titers from AM1-OVA, triAM1(Gly) <sub>2</sub> -OVA and AM1(Gly) <sub>2</sub> -OVA Vaccinated Mice
(n = 5-6) as Determined by ELISA Using AM1-BSA, triAM1(Gly) <sub>2</sub> -BSA and AM1(Gly) <sub>2</sub> -BSA Coated Plates <sup>a</sup>

Vaccine	<b>Copies per</b>	Titers (AM1-BSA coating antigen)				
	OVA molecule	21 d	42 d	56 d		
AM1-OVA	11.4	$\textbf{35617} \pm \textbf{15438}$	$\textbf{30238} \pm 11228$	$\textbf{54755} \pm \textbf{16564}$		
triAM1(Gly)2-OVA	1.98 (≡5.93)	$44359\pm7502$	$\textbf{30723} \pm \textbf{2273}$	$\textbf{72054} \pm \textbf{18542}$		
AM1(Gly) <sub>2</sub> -OVA	5.79	$\textbf{63591} \pm \textbf{24336}$	$\textbf{44531} \pm \textbf{13887}$	$68446 \pm 30321$		
Vaccine	Copies per	Titers (triAM1(Gly) <sub>2</sub> -BSA coating antigen)				
	OVA molecule	21 d	42 d	56 d		
AM1-OVA	11.4	$\textbf{51475} \pm \textbf{21549}$	$\textbf{41039} \pm 14596$	$\textbf{83544} \pm \textbf{29388}$		
triAM1(Gly)2-OVA	1.98 (≡5.93)	$\textbf{73908} \pm \textbf{11850}$	$56090 \pm 3665$	$135093 \pm 39113$		
AM1(Gly) <sub>2</sub> -OVA	5.79	$58454 \pm 19659$	$\textbf{50492} \pm \textbf{15773}$	$\textbf{83751} \pm \textbf{34018}$		
Vaccine	Copies per Titers (AM1(Gly) <sub>2</sub> -BSA coating antiger					
	OVA molecule	21 d	42 d	56 d		
AM1-OVA	11.4	$\textbf{35849} \pm \textbf{13350}$	$\textbf{30987} \pm \textbf{14505}$	$\textbf{74584} \pm \textbf{27116}$		
triAM1(Gly)2-OVA	<b>1.98</b> (≡1.53)	$\textbf{45842} \pm \textbf{12611}$	$\textbf{35825} \pm \textbf{4614}$	$\textbf{63915} \pm \textbf{16493}$		

<sup>a</sup>Data were obtained in duplicate. Errors represent SEM.





**Figure S3**. Anti-nicotine antibody affinities and concentrations from AM1-OVA, triAM1(Gly)<sub>2</sub>-OVA and AM1(Gly)<sub>2</sub>-OVA vaccinated mice (n = 5-6) using pooled plasma (56 d) as determined by competitive RIA. Data for AM1(Gly)<sub>2</sub> were obtained in triplicate, and data for AM1 and triAM1(Gly)<sub>2</sub> were obtained in duplicate. Errors represent SEM.

NMR Spectra

